Ajanta Pharma Limited (AJANTPHARM) share price
₹3464.80 on NSE as of 2026-09-04. -1.60% on the day. market cap ₹43,288 Cr. P/E 38.1. 52-week range ₹2388.40 to ₹3718.20. Healthcare.
Ajanta Pharma Q1 FY27: ₹487 Crore From America, ₹255 Crore From a Shipping Lane That Stopped Working
At a glance
Revenue for the June 2026 quarter came in at ₹1,626 crore, up 25% from ₹1,303 crore a year earlier and up 14% from ₹1,422 crore in the March quarter. PAT reached ₹334 crore against ₹255 crore, a 31% climb. EPS printed ₹26.75 versus ₹20.44. The board approved a first interim dividend of ₹32 per share on a ₹2 face value — roughly ₹400 crore going out the door on a record date of 5 August 2026.
Underneath the headline, the geographies went in opposite directions with some enthusiasm. US generics did ₹487 crore against ₹310 crore, up 57%. Africa branded generics did ₹295 crore against ₹228 crore, up 30%. Africa institutional went from ₹38 crore to ₹70 crore, up 83%. And Asia branded generics did ₹255 crore against ₹304 crore — down 16%, which management attributes to continued geopolitical developments in the Middle East disrupting supply chains and affecting dispatches. Demand, per management, was never the constraint; the ships were.
Operating profit was ₹424 crore at a 26% margin. Other income was ₹71 crore, and the filing notes it contains a ₹50.47 crore foreign exchange gain, while other expenses of ₹493 crore carry a ₹30.59 crore forex loss. Management calls this an anomaly in the reported lines and gives EBITDA guidance excluding forex altogether.
A quarter where one region's ships didn't sail and the consolidated number still grew 25% has a certain arithmetic to it. We'll get to which region did the heavy lifting, and why management refuses to extrapolate it.
Introduction
Incorporated in 1979, Ajanta Pharma Limited is a specialty pharmaceutical formulation company built primarily around branded generics, with ground presence in 33+ countries. The company describes itself as focused on India, Asia and Africa for branded generics, with a separate generics business in the USA and an institutional antimalarial business in Africa. Registered office is Ajanta Tower in Andheri East, Mumbai. Yogesh M. Agrawal is Managing Director; Mannalal B. Agrawal is Chairman, Madhusudan Agarwal Vice Chairman, and Rajesh M Agarwal Jt. Managing Director, per CARE's rating documentation.
The last twelve months have been busy in ways that don't all show up in a revenue line. In December 2025, Ajanta in-licensed Semaglutide from Biocon for marketing in 26 countries, with approvals expected late 2026 to early 2027. In August 2025, Income Tax Authorities carried out search operations; the company filed its return for the block period 1 April 2019 to 17 November 2025 on 6 April 2026, and the auditors note the consequent impact, if any, is currently not ascertainable. In April 2026, a US FDA inspection at the Paithan plant concluded with a Form 483 carrying five observations. In June 2026, promoter Aayush Agrawal created a pledge on 28,55,925 shares for a new loan.
Structurally, the company runs seven manufacturing facilities in India, two of them US FDA approved and the rest compliant with WHO cGMP standards, plus an R&D centre in Mumbai staffed by 850+ scientists. FY26 saw 53 new products launched across markets, with total R&D expense at about 5% of revenue.
CARE Ratings reaffirmed CARE AA+; Stable / CARE A1+ on ₹72.50 crore of bank facilities in August 2025, citing consistent improvement in performance and minimal dependence on debt.
FY26 closed at ₹5,453 crore of revenue and ₹1,056 crore of PAT. The June quarter is the first data point of FY27, and it arrived with the US doing something the company itself declines to promise will continue.
Business model
Ajanta makes pills, drops and creams, then sells them under its own brand names to doctors who have been visited very persistently by one of 6,050+ medical representatives. That last number is the actual business model. Two-thirds of revenue comes from branded generics, which means the molecule is off-patent and available from anyone, and the entire commercial exercise is convincing a prescriber to write your name for it.
The therapy mix in India tells you where the persuasion is aimed: cardiology 37%, ophthalmology 29%, dermatology 22%, pain management 10%, with nephrology and gynaecology at 1% each. These are chronic categories — 65% of the India portfolio — which is the pharma equivalent of a subscription business, except the customer renewal mechanism is a condition that doesn't go away.
The brand shelf, per CARE, includes Met XL for hypertension, Atorfit and Rosofit and Cinod in cardiology, Melacare in dermatology, Bimat and Soft Drops in ophthalmology, Feburic in pain management, and Artefan in antimalarials. Company disclosure puts it at 500+ brands, with about 50% of products first to market, 330+ products in India across six therapy segments and 220+ across eight segments in Asia and Africa.
Then there's the US, which operates on entirely different physics. No brands, no medical reps, no sub-therapeutic leadership — just 55 active ANDAs excluding five tentative, 51 products on shelf, 17 pending approvals, and a filing target of 8–12. You file, you wait for the FDA, you launch, and then competitors arrive and the price does what prices do. Management is explicit that it expects some competition, price erosion, and some loss in market share.
The fourth business is Africa institutional — antimalarials sold to institutions, first generic prequalified by WHO, 1 billion+ patients treated. It did ₹70 crore in the quarter, or roughly 4% of revenue, and swings around cheerfully: ₹249 crore in FY24, ₹147 crore in FY25, ₹160 crore in FY26.
Four businesses, four sets of rules, one P&L. The medical rep army is what holds three of the four together; the fourth answers to a regulator in Maryland.
Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Ajanta Pharma Limited.
Companies in the same industry as Ajanta Pharma Limited
Pharmaceuticals